UNSPSC 51142300: Narcotic antagonists

This classification denotes agents inhibiting the effect of narcotics, such as opiates and opiods, on the central nervous system.

UNSPSC 51142300 Narcotic antagonists is a Class code encompassing pharmaceutical products used to reverse opioid overdose and related drug-disposal systems, as well as broader pharmacy benefit procurement supporting state and local health initiatives. State and local governments procure naloxone (Narcan), safe drug deactivation systems, and related pharmaceutical supplies through this code, with issuing bodies spanning county health departments, state health agencies, and cooperative purchasing alliances. The scope extends from point-of-care overdose reversal supplies to large-scale pharmacy benefit management programs that coordinate drug sourcing across multiple jurisdictions and wholesalers.

Recent opportunities show activity across Florida, California, Texas, and Minnesota. The County of Orange, California (Sheriff-Coroner Department) posted IFB0602941301CLM in March 2026 seeking narcotics and narcotic paraphernalia onsite and offsite destruction services with an estimated 20,000 pounds of initial destruction and 10,000 pounds quarterly, with a three-year contract term and options for two additional one-year renewals; the solicitation offers Local Small Business and Disabled Veteran Business Enterprise preferences. Seminole County, Florida released IFB60459723LAS in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a two-year initial term plus one-year renewal option. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026; the RFP emphasizes price competitiveness (75 percent of evaluation weight) and requires cGMP and Drug Supply Chain Security Act compliance. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 as an exploratory market-intelligence initiative seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels.